Skip to main content
World Journal of Gastroenterology logoLink to World Journal of Gastroenterology
. 2013 Sep 7;19(33):5439–5445. doi: 10.3748/wjg.v19.i33.5439

Epigenetics of hepatocellular carcinoma: Role of microRNA

Sharad Khare 1,2, Qiong Zhang 1,2, Jamal A Ibdah 1,2
PMCID: PMC3761096  PMID: 24023486

Abstract

Hepatocellular carcinoma (HCC) represents a major form of primary liver cancer in adults. MicroRNAs (miRs), small non-coding single-stranded RNAs of 19-24 nucleotides in length, negatively regulate the expression of many target genes at the post-transcriptional and/or translational levels and play a critical role in the initiation and progression of HCC. In this review we have summarized the information of aberrantly expressed miRs in HCC, their mechanism of action and relationship to cancer. The recent advances in HCC research reveal that miRs regulate expression of various oncogenes and tumor suppressor genes, thereby contributing to the modulation of diverse biological processes including proliferation, apoptosis, epithelial to mesenchymal transition and metastasis. From a clinical viewpoint, polymorphisms within miR-binding sites are associated with the risk of HCC. Polymorphisms in miR related genes have been shown to correlate with survival or treatment outcome in patients. Furthermore, the review focuses on the potential role of miRs as novel biomarkers and their translational applications for diagnosis and therapy in HCC. With further insights into miR deregulation in HCC, it is expected that novel miR-based therapeutics will arise. Also, we orient the readers to other reviews that may provide better understanding of miR research in HCC.

Keywords: MicroRNA, Cancer, Hepatocellular carcinoma, Biomarker, Polymorphism


Core tip: This review provides the relationship between microRNA (miR) and hepatocellular carcinoma and speculates on the progress that will be achieved through ongoing research. A research effort to identify genetic polymorphisms associated with cancer is emphasized. The review highlights that miR-based therapeutics, and diagnostic and prognostic systems should be used for patients.

INTRODUCTION

Liver cancer is the second and sixth leading cause of cancer related-death in males and females respectively. Hepatocellular carcinoma (HCC) that accounts for most of the primary liver cancers is the fifth most frequently diagnosed cancer worldwide. Early detection of HCC is needed because the best indicator of prognosis is based on the stage of the disease. About 90% of HCC cases arise from cirrhosis and the disease is strongly associated with several risks factors, including hepatitis B and C infections, alcohol abuse, primary biliary cirrhosis, autoimmune hepatitis and nonalcoholic steatohepatitis[1]. Epigenetic changes in microRNAs (miRs) and their target gene expression may provide tools and opportunities for detection and therapeutic intervention in HCC.

MiRs, a class of non-coding RNAs with lengths of 19- to -25 nucleotides (nt), act as post-transcriptional regulators by binding to 3’-untranslated region (3’UTR) of target messenger RNA (mRNA). MiRs function as endogenous suppressor of gene expression by inducing either mRNA degradation or translational repression. The promoters of MiR genes are regulated by transcription factors, co-activators, enhancers and suppressors similar to protein coding genes. Thus, proto-oncogene c-myc[2,3] and tumor suppressor p53[4] transactivate miRs in HCC. In a genomic cluster the individual miRs are often expressed at different times from the same pri-miR. Pri-miRs are transcribed in the nucleus into a 70-100 nt hairpin-shaped structure and the process is catalyzed by Drosha, which is associated with cofactor DGCR8 and other proteins. After translocation to the cytoplasm by Exportin5, miRs are cleaved into a 19-25 nt miR duplex by enzyme Dicer. One strand of the duplex is then incorporated into the RNA-induced silencing complex (RISC) for its mRNA targets. MiRs function as endogenous suppressor of gene expression by binding of RISC to the 3’UTR of target mRNAs and inducing either mRNA degradation or translational repression. The mRNA degradation is induced if miR binds completely or almost completely, however, if the binding is incomplete, miR represses translation of mRNA. Each step of the process is well regulated, and dysfunction at any level can result in inappropriate miR functions. Gene silencing is the most methodically studied role of miRs, however, they can up-regulate gene transcription during cell cycle arrest and, therefore, overexpression of miRs in human cancers hinted to probable oncogenic functions of miRs. As discussed earlier a direct binding of miR to 5’UTR or promoter of the target genes activate rather inhibit gene expression[5].

Analogous to the protein-coding genes, epigenetic mechanisms, for example, CpG island hypermethylation[6-8] and histone modifications[9] also regulate miR expression in HCC. MiRs that are transcribed from CpG islands undergo DNA hypermethylation-coupled repression due to binding of the transcriptional repressor methyl CpG binding proteins. Epigenetic regulation of miRs might be more common than reported so far as approximately 16% of the annotated human miRs are located within 1000 bp of a CpG island. To date, more than 1000 human miRs have been identified and each miR control hundreds of genes. It has been suggested that miRs regulate the translation rate of more than 60% of protein coding genes.

ABERRANT EXPRESSION OF MICRORNAS IN HCC

MiRs play a central role in basic biological processes such as cellular differentiation, proliferation, apoptosis, migration and invasion. MiR expression profiles are different between normal tissue and derived tumors and between distinct tumor types. Protein coding genes of cell cycle, apoptosis, and metastasis are direct targets of miRs in HCC[10]. Microarray studies have identified a number of miRs that are either up-or down-regulated[11]. Down-regulation of subsets of miRs is a common finding in HCC, indicating that some of these miRs may act as putative tumor suppressor genes. Restoration of tumor suppressive miRs leads to cell cycle block, increased apoptosis and reduced tumor angiogenesis and metastasis by inhibiting migration and invasion. On the contrary, onco-miRs that are up-regulated in HCC potentially target many tumor suppressive genes. Experimental suppression of onco-miRs helps restoring expression of tumor suppressive genes that initiates apoptosis and inhibits cell proliferation, angiogenesis and metastasis in HCC. In general, to investigate the role of deregulated miRs in HCC, miR expression vectors and mature miR mimics or inhibitors (antagomirs) are transfected in HCC cell lines. Further, to confirm the target genes of respective miRs, 3’UTR luciferase vectors (empty luciferase vector or luciferase vector containing wild-type or mutant-type target gene 3’UTR) are utilized for reporter assays. Major down- and up-regulated miRs and their target genes in HCC are discussed in Table 1.

Table 1.

Down-regulated microRNA in hepatocellular carcinoma and their characteristics

miRs Targets Characteristics
Down-regulated
miR-1 ET1 Proliferation[52]
miRs-7a, -7b, -7c, -7d, -7f-1, -7d Caspase-3, HMGA2, C-myc, Bcl-xl Proliferation, apoptosis[2,23,53-58]
miR-101 Mcl-1, SOX-9, EZH2, EED, DNMT3A Proliferation, apoptosis[59-61]
miRs-122 Bcl-w, ADAM-1, Wnt-1 Angiogenesis, apoptosis, Metastasis[45,62-64]
miR-125a, -125b MMP11, SIRT7, VEGF-A, LIN28B2, Bcl-2, Mcl-1, Bcl-w Angiogenesis, apoptosis, metastasis, proliferation[65-70]
miR-139 c-Fos, Rho-kinase-2 Metastasis[30,71]
miR-145 IRS1-2, OCT4 Insulin-like growth factor pathway, Stem-like cells tumorigenicity[31,72]
miR-195 CDK6, E2F3, cyclinD1 Proliferation, apoptosis, tumorigenicity[73,74]
miR-199a-3p, -199-5p c-Met, mTOR, PAK4, DDR1, caveolin-2 Proliferation, autophagy, metastasis[9,75-78]
miRs-214 HDGF, catenin Proliferation, angiogenesis, metastasis[79-81]
Up-regulated
miR-10a EphA4, CADM1 EMT, metastasis[33,82]
miR-21 Pten, RhoB, PDCD4 Drug Resistance, metastasis[49,83-85]
miR-221 Bmf, DDIT4, Arnt, CDKN1B/p27, CDKN1C/p57 Angiogenesis, apoptosis, proliferation[86-89]
miRs-224 Yin Yang1/Raf-1 kinase, NFκB pathways, apoptosis inhibitor-5 Proliferation, apoptosis, metastasis[90-93]

miRs: MicroRNAs; EMT: Epithelial-mesenchymal transition.

CLINICAL SIGNIFICANCE AND TRANSLATIONAL APPLICATIONS OF MICRORNAS IN HCC

Single nucleotide polymorphism in miRs

Single nucleotide polymorphisms (SNPs) in miRs and their targets have been associated with risk of various cancers. Due to the stringent recognition requirement needed by the miR and the binding region on its target gene, it is rather conceivable that SNPs could have functional implications on the post-transcriptional regulation of target genes. An SNP could either weaken a known miR target or create a sequence match to the miR that was not previously associated with the given mRNA. Changes in the expression pattern of a gene could therefore influence a person’s risk of disease. Polymorphisms in miR-34b-c/rs4938723[12], miR-101-1/rs7536540[13], miR-101-2/rs-12375841[13], miR-106b-25/rs99985[14] and miR-196a-2/rs11614913[15] are positively associated with HCC. On the contrary, miR-371-373/rs3859501[16] and miR-149c/rs2292832[17] are negatively associated with HCC risk. Also, a positive association of HCC risk has been demonstrated with polymorphisms in miR target genes IL-1/rs3783553 (miR-122 and miR-378)[18], -TrCP/rs16405 (miR-920)[19], IFNAR1/rs17875871 (miR-1231)[20], ErbB4/rs6147150 (miR-let-7c)[21] and COL1A2/rs3917 (miR-let-7g)[22].

miRs as biomarkers in HCC

miRs are prognostic markers of HCC. Down-regulation of miR-let-7g[23], -22[24], -26[25], -29[26], -99a[27], -122[28], -124[29], -139[30], -145[31] and -199b[32] is associated with poor prognosis, increased risk of aggressive tumor recurrence and shorter disease free survival. Similarly, up-regulation of HCC associated miRs-10b[33], -17-5p[34], -21[35], -135a[36], -155[37], -182[38], -221[35], and -222[35,39] is linked to poor prognosis. Studies have shown that miRs are protected from enzymatic cleavage by RNAse in blood and therefore miR expression profile in serum or plasma could also be utilized as novel diagnostic markers. More than 20 miRs in serum and/or plasma have been associated with HCC detection. The expression profile of miRs-500, -92a, -25, -375 and let-7f could identify HCC cases from controls[40-43]. Furthermore, Zhou et al[44] demonstrated that miR-122, -192, -21, -223, -26a, -27a and-801a helped detecting early-stage HCC with high diagnostic accuracy.

miRs as therapeutic targets in HCC

Tumor suppressive miRs that are expressed in normal liver, however, are down-regulated in tumor tissues during tumorigenesis and metastasis. For treatment, a good strategy would be to replenish such miRs systemically in HCC patients. Such miR replacement therapies have been demonstrated in the case of miRs -26a[3], -122[45], and -124[46] in mice models of HCC. Conversely, suppression of oncomir-221[47,48] by antagomirs resulted in prolonged survival and reduction of tumors. As targeted gene therapies are gaining interest in cancer treatment, miR as a therapeutic target would be more efficient since single miR can control multiple deranged genes in HCC. However, this hypothesis is yet to be tested in HCC patients. Further, chemotherapeutics kill normal cells and pose significant toxicities in cancer patients, a non-discriminatory behavior of chemotherapy drugs. In mice models, as discussed above, no such toxicity was observed when miRs were used to treat HCC. In this regard, miRs also influence sensitivity of tumors to anticancer drugs. Tumors with high expression of oncomiR-21[49] and -181b[50] were resistant to IFN-5FU combination therapy and doxorubicin treatment respectively. A strategy to suppress these miRs by antagomirs might be useful in increasing drug efficacy. Similarly, studies have demonstrated that restoration of tumor suppressive miR-122[51] makes HCC cells more sensitive to Sorafenib treatment via down-regulation of multidrug resistance genes.

CONCLUSION

miRs control expression of many target genes in HCC. miR profiling reveals molecular mechanisms of pathogenesis and hidden visions into early detection and treatment of HCC. Hundreds of miRs have been identified to date; however, computer models suggest there may be hundreds more. There are several online tools available for researchers and clinicians to identify and predict the targets of miRs. As research continues to verify in silico predictions, miR profiling will be a prominent tool for identification of differentially expressed miRs in HCC. More information from genome-wide association studies, assisted by high resolution SNP arrays and the next-generation sequencing technology, is anticipated to identify increasing number of polymorphisms in HCC specific miRs and their 3’UTR targets. For future studies, we should consider miRs and their regulatory networks in order to comprehend the complex processes underlying HCC transformation.

Footnotes

Supported by VA Merit Award, project ID 1171590; NCI Cancer Prevention RO3 Grant, CA150081-03 to Khare S; Raymond E and Vaona H Peck Chair in Cancer Research to Ibdah JA

P- Reviewers Cappelli A, Francis H, Hasegawa K S- Editor Gou SX L- Editor A E- Editor Zhang DN

References

  • 1.Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist. 2010;15 Suppl 4:14–22. doi: 10.1634/theoncologist.2010-S4-14. [DOI] [PubMed] [Google Scholar]
  • 2.Wang Z, Lin S, Li JJ, Xu Z, Yao H, Zhu X, Xie D, Shen Z, Sze J, Li K, et al. MYC protein inhibits transcription of the microRNA cluster MC-let-7a-1~let-7d via noncanonical E-box. J Biol Chem. 2011;286:39703–39714. doi: 10.1074/jbc.M111.293126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Zhu Y, Lu Y, Zhang Q, Liu JJ, Li TJ, Yang JR, Zeng C, Zhuang SM. MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein. Nucleic Acids Res. 2012;40:4615–4625. doi: 10.1093/nar/gkr1278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Fornari F, Milazzo M, Chieco P, Negrini M, Marasco E, Capranico G, Mantovani V, Marinello J, Sabbioni S, Callegari E, et al. In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. J Pathol. 2012;227:275–285. doi: 10.1002/path.3995. [DOI] [PubMed] [Google Scholar]
  • 5.Zhang LY, Liu M, Li X, Tang H. miR-490-3p modulates cell growth and epithelial to mesenchymal transition of hepatocellular carcinoma cells by targeting endoplasmic reticulum-Golgi intermediate compartment protein 3 (ERGIC3) J Biol Chem. 2013;288:4035–4047. doi: 10.1074/jbc.M112.410506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Jung CJ, Iyengar S, Blahnik KR, Ajuha TP, Jiang JX, Farnham PJ, Zern M. Epigenetic modulation of miR-122 facilitates human embryonic stem cell self-renewal and hepatocellular carcinoma proliferation. PLoS One. 2011;6:e27740. doi: 10.1371/journal.pone.0027740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B, Savic R, Ward SC, Thung S, Chiang DY, et al. MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology. 2011;140:1618–1628.e16. doi: 10.1053/j.gastro.2011.02.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Zhang S, Shan C, Kong G, Du Y, Ye L, Zhang X. MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-κB-inducing kinase (NIK) Oncogene. 2012;31:3607–3620. doi: 10.1038/onc.2011.523. [DOI] [PubMed] [Google Scholar]
  • 9.Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q, Qin L, Wu X, Zheng Y, Yang Y, et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell. 2011;19:232–243. doi: 10.1016/j.ccr.2011.01.001. [DOI] [PubMed] [Google Scholar]
  • 10.Liu WR, Shi YH, Peng YF, Fan J. Epigenetics of hepatocellular carcinoma: a new horizon. Chin Med J (Engl) 2012;125:2349–2360. [PubMed] [Google Scholar]
  • 11.Sun J, Lu H, Wang X, Jin H. MicroRNAs in hepatocellular carcinoma: regulation, function, and clinical implications. ScientificWorldJournal. 2013;2013:924206. doi: 10.1155/2013/924206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Xu Y, Liu L, Liu J, Zhang Y, Zhu J, Chen J, Liu S, Liu Z, Shi H, Shen H, et al. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer. 2011;128:412–417. doi: 10.1002/ijc.25342. [DOI] [PubMed] [Google Scholar]
  • 13.Bae JS, Kim JH, Pasaje CF, Cheong HS, Lee TH, Koh IS, Lee HS, Kim YJ, Shin HD. Association study of genetic variations in microRNAs with the risk of hepatitis B-related liver diseases. Dig Liver Dis. 2012;44:849–854. doi: 10.1016/j.dld.2012.04.021. [DOI] [PubMed] [Google Scholar]
  • 14.Liu Y, Zhang Y, Wen J, Liu L, Zhai X, Liu J, Pan S, Chen J, Shen H, Hu Z. A genetic variant in the promoter region of miR-106b-25 cluster and risk of HBV infection and hepatocellular carcinoma. PLoS One. 2012;7:e32230. doi: 10.1371/journal.pone.0032230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Guo J, Jin M, Zhang M, Chen K. A genetic variant in miR-196a2 increased digestive system cancer risks: a meta-analysis of 15 case-control studies. PLoS One. 2012;7:e30585. doi: 10.1371/journal.pone.0030585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Kwak MS, Lee DH, Cho Y, Cho EJ, Lee JH, Yu SJ, Yoon JH, Lee HS, Kim CY, Cheong JY, et al. Association of polymorphism in pri-microRNAs-371-372-373 with the occurrence of hepatocellular carcinoma in hepatitis B virus infected patients. PLoS One. 2012;7:e41983. doi: 10.1371/journal.pone.0041983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Kim WH, Min KT, Jeon YJ, Kwon CI, Ko KH, Park PW, Hong SP, Rim KS, Kwon SW, Hwang SG, et al. Association study of microRNA polymorphisms with hepatocellular carcinoma in Korean population. Gene. 2012;504:92–97. doi: 10.1016/j.gene.2012.05.014. [DOI] [PubMed] [Google Scholar]
  • 18.Gao Y, He Y, Ding J, Wu K, Hu B, Liu Y, Wu Y, Guo B, Shen Y, Landi D, et al. An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1alpha 3’ untranslated region confers risk for hepatocellular carcinoma. Carcinogenesis. 2009;30:2064–2069. doi: 10.1093/carcin/bgp283. [DOI] [PubMed] [Google Scholar]
  • 19.Chen S, He Y, Ding J, Jiang Y, Jia S, Xia W, Zhao J, Lu M, Gu Z, Gao Y. An insertion/deletion polymorphism in the 3’ untranslated region of beta-transducin repeat-containing protein (betaTrCP) is associated with susceptibility for hepatocellular carcinoma in Chinese. Biochem Biophys Res Commun. 2010;391:552–556. doi: 10.1016/j.bbrc.2009.11.096. [DOI] [PubMed] [Google Scholar]
  • 20.Zhou C, Yu Q, Chen L, Wang J, Zheng S, Zhang J. A miR-1231 binding site polymorphism in the 3’UTR of IFNAR1 is associated with hepatocellular carcinoma susceptibility. Gene. 2012;507:95–98. doi: 10.1016/j.gene.2012.06.073. [DOI] [PubMed] [Google Scholar]
  • 21.Yu Q, Zhou CX, Chen NS, Zheng SD, Shen LM, Zhang JK. A polymorphism within ErbB4 is associated with risk for hepatocellular carcinoma in Chinese population. World J Gastroenterol. 2012;18:383–387. doi: 10.3748/wjg.v18.i4.383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Zhu Z, Jiang Y, Chen S, Jia S, Gao X, Dong D, Gao Y. An insertion/deletion polymorphism in the 3’ untranslated region of type I collagen a2 (COL1A2) is associated with susceptibility for hepatocellular carcinoma in a Chinese population. Cancer Genet. 2011;204:265–269. doi: 10.1016/j.cancergen.2011.03.007. [DOI] [PubMed] [Google Scholar]
  • 23.Ji J, Zhao L, Budhu A, Forgues M, Jia HL, Qin LX, Ye QH, Yu J, Shi X, Tang ZY, et al. Let-7g targets collagen type I alpha2 and inhibits cell migration in hepatocellular carcinoma. J Hepatol. 2010;52:690–697. doi: 10.1016/j.jhep.2009.12.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Zhang J, Yang Y, Yang T, Liu Y, Li A, Fu S, Wu M, Pan Z, Zhou W. microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br J Cancer. 2010;103:1215–1220. doi: 10.1038/sj.bjc.6605895. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009;361:1437–1447. doi: 10.1056/NEJMoa0901282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH, Zhuang SM. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology. 2010;51:836–845. doi: 10.1002/hep.23380. [DOI] [PubMed] [Google Scholar]
  • 27.Li D, Liu X, Lin L, Hou J, Li N, Wang C, Wang P, Zhang Q, Zhang P, Zhou W, et al. MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem. 2011;286:36677–36685. doi: 10.1074/jbc.M111.270561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 2009;28:3526–3536. doi: 10.1038/onc.2009.211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH, Chen SP, Bian XW, Guan XY, Lin MC, Zeng YX, et al. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut. 2012;61:278–289. doi: 10.1136/gut.2011.239145. [DOI] [PubMed] [Google Scholar]
  • 30.Wong CC, Wong CM, Tung EK, Au SL, Lee JM, Poon RT, Man K, Ng IO. The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology. 2011;140:322–331. doi: 10.1053/j.gastro.2010.10.006. [DOI] [PubMed] [Google Scholar]
  • 31.Jia Y, Liu H, Zhuang Q, Xu S, Yang Z, Li J, Lou J, Zhang W. Tumorigenicity of cancer stem-like cells derived from hepatocarcinoma is regulated by microRNA-145. Oncol Rep. 2012;27:1865–1872. doi: 10.3892/or.2012.1701. [DOI] [PubMed] [Google Scholar]
  • 32.Wang C, Song B, Song W, Liu J, Sun A, Wu D, Yu H, Lian J, Chen L, Han J. Underexpressed microRNA-199b-5p targets hypoxia-inducible factor-1α in hepatocellular carcinoma and predicts prognosis of hepatocellular carcinoma patients. J Gastroenterol Hepatol. 2011;26:1630–1637. doi: 10.1111/j.1440-1746.2011.06758.x. [DOI] [PubMed] [Google Scholar]
  • 33.Li QJ, Zhou L, Yang F, Wang GX, Zheng H, Wang DS, He Y, Dou KF. MicroRNA-10b promotes migration and invasion through CADM1 in human hepatocellular carcinoma cells. Tumour Biol. 2012;33:1455–1465. doi: 10.1007/s13277-012-0396-1. [DOI] [PubMed] [Google Scholar]
  • 34.Chen L, Jiang M, Yuan W, Tang H. miR-17-5p as a novel prognostic marker for hepatocellular carcinoma. J Invest Surg. 2012;25:156–161. doi: 10.3109/08941939.2011.618523. [DOI] [PubMed] [Google Scholar]
  • 35.Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G, Voros D. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog. 2013;52:297–303. doi: 10.1002/mc.21864. [DOI] [PubMed] [Google Scholar]
  • 36.Liu S, Guo W, Shi J, Li N, Yu X, Xue J, Fu X, Chu K, Lu C, Zhao J, et al. MicroRNA-135a contributes to the development of portal vein tumor thrombus by promoting metastasis in hepatocellular carcinoma. J Hepatol. 2012;56:389–396. doi: 10.1016/j.jhep.2011.08.008. [DOI] [PubMed] [Google Scholar]
  • 37.Han ZB, Chen HY, Fan JW, Wu JY, Tang HM, Peng ZH. Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J Cancer Res Clin Oncol. 2012;138:153–161. doi: 10.1007/s00432-011-1076-z. [DOI] [PubMed] [Google Scholar]
  • 38.Wang J, Li J, Shen J, Wang C, Yang L, Zhang X. MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma. BMC Cancer. 2012;12:227. doi: 10.1186/1471-2407-12-227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Wong QW, Ching AK, Chan AW, Choy KW, To KF, Lai PB, Wong N. MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin Cancer Res. 2010;16:867–875. doi: 10.1158/1078-0432.CCR-09-1840. [DOI] [PubMed] [Google Scholar]
  • 40.Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997–1006. doi: 10.1038/cr.2008.282. [DOI] [PubMed] [Google Scholar]
  • 41.Yamamoto Y, Kosaka N, Tanaka M, Koizumi F, Kanai Y, Mizutani T, Murakami Y, Kuroda M, Miyajima A, Kato T, et al. MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers. 2009;14:529–538. doi: 10.3109/13547500903150771. [DOI] [PubMed] [Google Scholar]
  • 42.Shigoka M, Tsuchida A, Matsudo T, Nagakawa Y, Saito H, Suzuki Y, Aoki T, Murakami Y, Toyoda H, Kumada T, et al. Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development. Pathol Int. 2010;60:351–357. doi: 10.1111/j.1440-1827.2010.02526.x. [DOI] [PubMed] [Google Scholar]
  • 43.Li LM, Hu ZB, Zhou ZX, Chen X, Liu FY, Zhang JF, Shen HB, Zhang CY, Zen K. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res. 2010;70:9798–9807. doi: 10.1158/0008-5472.CAN-10-1001. [DOI] [PubMed] [Google Scholar]
  • 44.Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, Wang JF, Zhang Z, Lu S, Huang X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol. 2011;29:4781–4788. doi: 10.1200/JCO.2011.38.2697. [DOI] [PubMed] [Google Scholar]
  • 45.Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, Chen CM, Lin CD, Liao YL, Wang JL, Chau YP, et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology. 2009;49:1571–1582. doi: 10.1002/hep.22806. [DOI] [PubMed] [Google Scholar]
  • 46.Lang Q, Ling C. MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA. Biochem Biophys Res Commun. 2012;426:247–252. doi: 10.1016/j.bbrc.2012.08.075. [DOI] [PubMed] [Google Scholar]
  • 47.Park JK, Kogure T, Nuovo GJ, Jiang J, He L, Kim JH, Phelps MA, Papenfuss TL, Croce CM, Patel T, et al. miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res. 2011;71:7608–7616. doi: 10.1158/0008-5472.CAN-11-1144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Callegari E, Elamin BK, Giannone F, Milazzo M, Altavilla G, Fornari F, Giacomelli L, D’Abundo L, Ferracin M, Bassi C, et al. Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology. 2012;56:1025–1033. doi: 10.1002/hep.25747. [DOI] [PubMed] [Google Scholar]
  • 49.Tomimaru Y, Eguchi H, Nagano H, Wada H, Tomokuni A, Kobayashi S, Marubashi S, Takeda Y, Tanemura M, Umeshita K, et al. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer. 2010;103:1617–1626. doi: 10.1038/sj.bjc.6605958. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Wang B, Hsu SH, Majumder S, Kutay H, Huang W, Jacob ST, Ghoshal K. TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene. 2010;29:1787–1797. doi: 10.1038/onc.2009.468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Bai S, Nasser MW, Wang B, Hsu SH, Datta J, Kutay H, Yadav A, Nuovo G, Kumar P, Ghoshal K. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem. 2009;284:32015–32027. doi: 10.1074/jbc.M109.016774. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Li D, Yang P, Li H, Cheng P, Zhang L, Wei D, Su X, Peng J, Gao H, Tan Y, et al. MicroRNA-1 inhibits proliferation of hepatocarcinoma cells by targeting endothelin-1. Life Sci. 2012;91:440–447. doi: 10.1016/j.lfs.2012.08.015. [DOI] [PubMed] [Google Scholar]
  • 53.Tsang WP, Kwok TT. Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis. 2008;13:1215–1222. doi: 10.1007/s10495-008-0256-z. [DOI] [PubMed] [Google Scholar]
  • 54.Di Fazio P, Montalbano R, Neureiter D, Alinger B, Schmidt A, Merkel AL, Quint K, Ocker M. Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines. Exp Cell Res. 2012;318:1832–1843. doi: 10.1016/j.yexcr.2012.04.018. [DOI] [PubMed] [Google Scholar]
  • 55.Zhu XM, Wu LJ, Xu J, Yang R, Wu FS. Let-7c microRNA expression and clinical significance in hepatocellular carcinoma. J Int Med Res. 2011;39:2323–2329. doi: 10.1177/147323001103900631. [DOI] [PubMed] [Google Scholar]
  • 56.Shah YM, Morimura K, Yang Q, Tanabe T, Takagi M, Gonzalez FJ. Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol Cell Biol. 2007;27:4238–4247. doi: 10.1128/MCB.00317-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Lan FF, Wang H, Chen YC, Chan CY, Ng SS, Li K, Xie D, He ML, Lin MC, Kung HF. Hsa-let-7g inhibits proliferation of hepatocellular carcinoma cells by downregulation of c-Myc and upregulation of p16(INK4A) Int J Cancer. 2011;128:319–331. doi: 10.1002/ijc.25336. [DOI] [PubMed] [Google Scholar]
  • 58.Shimizu S, Takehara T, Hikita H, Kodama T, Miyagi T, Hosui A, Tatsumi T, Ishida H, Noda T, Nagano H, et al. The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J Hepatol. 2010;52:698–704. doi: 10.1016/j.jhep.2009.12.024. [DOI] [PubMed] [Google Scholar]
  • 59.Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y, Zhuang SM. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 2009;69:1135–1142. doi: 10.1158/0008-5472.CAN-08-2886. [DOI] [PubMed] [Google Scholar]
  • 60.Wei X, Xiang T, Ren G, Tan C, Liu R, Xu X, Wu Z. miR-101 is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A. Cell Signal. 2013;25:439–446. doi: 10.1016/j.cellsig.2012.10.013. [DOI] [PubMed] [Google Scholar]
  • 61.Zhang Y, Guo X, Xiong L, Kong X, Xu Y, Liu C, Zou L, Li Z, Zhao J, Lin N. MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma. FEBS Lett. 2012;586:4362–4370. doi: 10.1016/j.febslet.2012.10.053. [DOI] [PubMed] [Google Scholar]
  • 62.Lin CJ, Gong HY, Tseng HC, Wang WL, Wu JL. miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun. 2008;375:315–320. doi: 10.1016/j.bbrc.2008.07.154. [DOI] [PubMed] [Google Scholar]
  • 63.Reddi HV, Madde P, Milosevic D, Hackbarth JS, Algeciras-Schimnich A, McIver B, Grebe SK, Eberhardt NL. The Putative PAX8/PPARγ Fusion Oncoprotein Exhibits Partial Tumor Suppressor Activity through Up-Regulation of Micro-RNA-122 and Dominant-Negative PPARγ Activity. Genes Cancer. 2011;2:46–55. doi: 10.1177/1947601911405045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Xu J, Zhu X, Wu L, Yang R, Yang Z, Wang Q, Wu F. MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/β-catenin pathway. Liver Int. 2012;32:752–760. doi: 10.1111/j.1478-3231.2011.02750.x. [DOI] [PubMed] [Google Scholar]
  • 65.Zhao A, Zeng Q, Xie X, Zhou J, Yue W, Li Y, Pei X. MicroRNA-125b induces cancer cell apoptosis through suppression of Bcl-2 expression. J Genet Genomics. 2012;39:29–35. doi: 10.1016/j.jgg.2011.12.003. [DOI] [PubMed] [Google Scholar]
  • 66.Alpini G, Glaser SS, Zhang JP, Francis H, Han Y, Gong J, Stokes A, Francis T, Hughart N, Hubble L, et al. Regulation of placenta growth factor by microRNA-125b in hepatocellular cancer. J Hepatol. 2011;55:1339–1345. doi: 10.1016/j.jhep.2011.04.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Kim JK, Noh JH, Jung KH, Eun JW, Bae HJ, Kim MG, Chang YG, Shen Q, Park WS, Lee JY, et al. Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology. 2013;57:1055–1067. doi: 10.1002/hep.26101. [DOI] [PubMed] [Google Scholar]
  • 68.Liang L, Wong CM, Ying Q, Fan DN, Huang S, Ding J, Yao J, Yan M, Li J, Yao M, et al. MicroRNA-125b suppressesed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. Hepatology. 2010;52:1731–1740. doi: 10.1002/hep.23904. [DOI] [PubMed] [Google Scholar]
  • 69.Bi Q, Tang S, Xia L, Du R, Fan R, Gao L, Jin J, Liang S, Chen Z, Xu G, et al. Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. PLoS One. 2012;7:e40169. doi: 10.1371/journal.pone.0040169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Fan DN, Tsang FH, Tam AH, Au SL, Wong CC, Wei L, Lee JM, He X, Ng IO, Wong CM. Histone lysine methyltransferase, suppressor of variegation 3-9 homolog 1, promotes hepatocellular carcinoma progression and is negatively regulated by microRNA-125b. Hepatology. 2013;57:637–647. doi: 10.1002/hep.26083. [DOI] [PubMed] [Google Scholar]
  • 71.Fan Q, He M, Deng X, Wu WK, Zhao L, Tang J, Wen G, Sun X, Liu Y. Derepression of c-Fos caused by microRNA-139 down-regulation contributes to the metastasis of human hepatocellular carcinoma. Cell Biochem Funct. 2013;31:319–324. doi: 10.1002/cbf.2902. [DOI] [PubMed] [Google Scholar]
  • 72.Law PT, Ching AK, Chan AW, Wong QW, Wong CK, To KF, Wong N. MiR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma. Carcinogenesis. 2012;33:1134–1141. doi: 10.1093/carcin/bgs130. [DOI] [PubMed] [Google Scholar]
  • 73.Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhuang SM. MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology. 2009;50:113–121. doi: 10.1002/hep.22919. [DOI] [PubMed] [Google Scholar]
  • 74.Yang X, Yu J, Yin J, Xiang Q, Tang H, Lei X. MiR-195 regulates cell apoptosis of human hepatocellular carcinoma cells by targeting LATS2. Pharmazie. 2012;67:645–651. [PubMed] [Google Scholar]
  • 75.Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL, Pollutri D, Croce CM, Bolondi L, Gramantieri L. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2010;70:5184–5193. doi: 10.1158/0008-5472.CAN-10-0145. [DOI] [PubMed] [Google Scholar]
  • 76.Shatseva T, Lee DY, Deng Z, Yang BB. MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2. J Cell Sci. 2011;124:2826–2836. doi: 10.1242/jcs.077529. [DOI] [PubMed] [Google Scholar]
  • 77.Shen Q, Cicinnati VR, Zhang X, Iacob S, Weber F, Sotiropoulos GC, Radtke A, Lu M, Paul A, Gerken G, et al. Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion. Mol Cancer. 2010;9:227. doi: 10.1186/1476-4598-9-227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Xu N, Zhang J, Shen C, Luo Y, Xia L, Xue F, Xia Q. Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell. Biochem Biophys Res Commun. 2012;423:826–831. doi: 10.1016/j.bbrc.2012.06.048. [DOI] [PubMed] [Google Scholar]
  • 79.Shih TC, Tien YJ, Wen CJ, Yeh TS, Yu MC, Huang CH, Lee YS, Yen TC, Hsieh SY. MicroRNA-214 downregulation contributes to tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma. J Hepatol. 2012;57:584–591. doi: 10.1016/j.jhep.2012.04.031. [DOI] [PubMed] [Google Scholar]
  • 80.Wang X, Chen J, Li F, Lin Y, Zhang X, Lv Z, Jiang J. MiR-214 inhibits cell growth in hepatocellular carcinoma through suppression of β-catenin. Biochem Biophys Res Commun. 2012;428:525–531. doi: 10.1016/j.bbrc.2012.10.039. [DOI] [PubMed] [Google Scholar]
  • 81.Xia H, Ooi LL, Hui KM. MiR-214 targets β-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma. PLoS One. 2012;7:e44206. doi: 10.1371/journal.pone.0044206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Yan Y, Luo YC, Wan HY, Wang J, Zhang PP, Liu M, Li X, Li S, Tang H. MicroRNA-10a is involved in the metastatic process by regulating Eph tyrosine kinase receptor A4-mediated epithelial-mesenchymal transition and adhesion in hepatoma cells. Hepatology. 2013;57:667–677. doi: 10.1002/hep.26071. [DOI] [PubMed] [Google Scholar]
  • 83.Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133:647–658. doi: 10.1053/j.gastro.2007.05.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Connolly EC, Van Doorslaer K, Rogler LE, Rogler CE. Overexpression of miR-21 promotes an in vitro metastatic phenotype by targeting the tumor suppressor RHOB. Mol Cancer Res. 2010;8:691–700. doi: 10.1158/1541-7786.MCR-09-0465. [DOI] [PubMed] [Google Scholar]
  • 85.Zhu Q, Wang Z, Hu Y, Li J, Li X, Zhou L, Huang Y. miR-21 promotes migration and invasion by the miR-21-PDCD4-AP-1 feedback loop in human hepatocellular carcinoma. Oncol Rep. 2012;27:1660–1668. doi: 10.3892/or.2012.1682. [DOI] [PubMed] [Google Scholar]
  • 86.Gramantieri L, Fornari F, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Croce CM, Bolondi L, Negrini M. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res. 2009;15:5073–5081. doi: 10.1158/1078-0432.CCR-09-0092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Giovannini C, Croce CM, Bolondi L, et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene. 2008;27:5651–5661. doi: 10.1038/onc.2008.178. [DOI] [PubMed] [Google Scholar]
  • 88.Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, Mazzaferro V, Lowe SW, Croce CM, Dejean A. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA. 2010;107:264–269. doi: 10.1073/pnas.0907904107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Yuan Q, Loya K, Rani B, Möbus S, Balakrishnan A, Lamle J, Cathomen T, Vogel A, Manns MP, Ott M, et al. MicroRNA-221 overexpression accelerates hepatocyte proliferation during liver regeneration. Hepatology. 2013;57:299–310. doi: 10.1002/hep.25984. [DOI] [PubMed] [Google Scholar]
  • 90.Zhang Y, Takahashi S, Tasaka A, Yoshima T, Ochi H, Chayama K. Involvement of microRNA-224 in cell proliferation, migration, invasion, and anti-apoptosis in hepatocellular carcinoma. J Gastroenterol Hepatol. 2013;28:565–575. doi: 10.1111/j.1440-1746.2012.07271.x. [DOI] [PubMed] [Google Scholar]
  • 91.Notarbartolo M, Giannitrapani L, Vivona N, Poma P, Labbozzetta M, Florena AM, Porcasi R, Muggeo VM, Sandonato L, Cervello M, et al. Frequent alteration of the Yin Yang 1/Raf-1 kinase inhibitory protein ratio in hepatocellular carcinoma. OMICS. 2011;15:267–272. doi: 10.1089/omi.2010.0096. [DOI] [PubMed] [Google Scholar]
  • 92.Scisciani C, Vossio S, Guerrieri F, Schinzari V, De Iaco R, D’Onorio de Meo P, Cervello M, Montalto G, Pollicino T, Raimondo G, et al. Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways. J Hepatol. 2012;56:855–861. doi: 10.1016/j.jhep.2011.11.017. [DOI] [PubMed] [Google Scholar]
  • 93.Wang Y, Lee AT, Ma JZ, Wang J, Ren J, Yang Y, Tantoso E, Li KB, Ooi LL, Tan P, et al. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem. 2008;283:13205–13215. doi: 10.1074/jbc.M707629200. [DOI] [PubMed] [Google Scholar]

Articles from World Journal of Gastroenterology : WJG are provided here courtesy of Baishideng Publishing Group Inc

RESOURCES